Diligence memo · auto-generated · as of July 2, 2026

General Fluidics Corp

General Fluidics Corp looks fair against its niche peers and is quiet on financing cadence.

SourceRaising on rhythm with a 4.5× step-up on the last round — momentum worth tracking before it's priced in.

Businessfiled

General Fluidics Corp operates in Other Health Care, based in WALTHAM.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

General Fluidics Corp has raised $35M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).

Largest single filing: $18M on 2024-07-16.

Most recent recorded round closed around 2024-07-16.

Valuation (modeled)modeled

Provath models General Fluidics Corp at approximately $119M (range $43M–$212M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.78× the median modeled value of Series B Other Health Care companies in 2022–2024 (91 peers) — value vs value, same stage and era. Within the normal band (78% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 17 months.

Last raise 24 mo ago; this sector typically re-raises about every 14 months.

Slightly overdue versus sector cadence.

The last round stepped up 4.5× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 90% of Other Health Care peers (5377 compared).

Modeled value ranks above 82% of those peers.

Closest niche peers: Code Biotherapeutics, Inc., Candesant Biomedical, Inc., Artis Holdings, LLC, GIO Blood Ltd, Clarapath, Inc..

Peoplefiled

10 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.